The E. coli antigen technology platform of Wantai BioPharm is one of its core advantages, which is a prokaryotic expression virus-like particle (VLP) vaccine technology system with independent intellectual property rights. This platform has broken through the key technical difficulties of prokaryotic expression protein particle assembly, and it features low production cost, high efficiency, easy scale-up, and high safety. Combining the advantages of virus-like particle vaccines such as good immunogenicity and high safety, it has been successfully applied to the Hepatitis E vaccine and the bivalent HPV vaccine, and has been extended to the development of all HPV types, as well as HBV virus and rotavirus vaccines. In addition, this platform also has good versatility and is suitable for the development of vaccines against various pathogens.

Wantai BioPharm has established a polysaccharide conjugate protein vaccine technology platform. This platform is mainly used for the development of polysaccharide conjugate vaccines. By conjugating polysaccharides with proteins, it can improve the immunogenicity and protective effect of vaccines. This technology is of great significance in preventing diseases caused by bacteria, such as infections caused by Streptococcus pneumoniae.

Wantai BioPharm has established an mRNA vaccine research and development technology platform. mRNA vaccine technology is one of the cutting-edge technologies in the field of vaccine research and development in recent years, with advantages such as fast research and development speed and relatively simple production process. Wantai BioPharm's layout on this platform demonstrates its innovation ability in the field of vaccine research and development and its grasp of future technological trends.

Wantai BioPharm has established a technology platform for the screening and development of new adjuvants. Adjuvants are an important component of vaccines and can enhance the immunogenicity of vaccines. Through this platform, Wantai BioPharm screens and develops new adjuvants with the aim of improving the effectiveness and safety of vaccines.

Wantai BioPharm not only has the advantageous murine antibody technology but also has the development capabilities of antibodies from large animals such as rabbit antibodies and sheep antibodies. It can be applied to the development and application of antibodies against different targets without species limitations, and the affinity and performance of the products are greatly guaranteed.